Scholarlink

Background <p>Loiasis affects millions in Central Africa and, though historically considered benign, emerging data suggest possible renal involvement. This study investigated the association between <i>Loa</i> microfilaremia and renal function.</p> Methods <p>We conducted a cross-sectional study in the Republic of Congo in May–June 2022. Renal function was assessed via estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease—Epidemiology Collaboration (CKD-EPI) and European Kidney Function Consortium (EKFC) equations, and proteinuria and/or haematuria (renal abnormalities, RAb). Multinomial logistic regression assessed associations between microfilarial density (MFD) and chronic kidney disease (CKD), using EKFC with Dubois correction. Population attributable fractions were estimated from a logistic model including <i>Loa</i> microfilaremia as a binary variable (present <i>versus</i> absent).</p> Results <p>Among 986 participants, CKD prevalence ranged from 13.4% [95% confidence interval (<i>CI</i>)&#xa0;11.4–15.7%, CKD-EPI] to 17.6% (95% <i>CI</i> 15.3–20.1%, EKFC) for KDIGO stages 1–5, and from 3.0% (95% <i>CI</i> 2.1–4.3%, CKD-EPI) to 7.6% (95% <i>CI</i> 6.1–9.4%, EKFC) for stages 3–5. <i>Loa</i> MFD was associated with higher odds of CKD, particularly in individuals with RAb. Compared to amicrofilaremic participants, those with <i>Loa</i> MFD ≥ 20 000 mf/ml had significantly increased risk: adjusted relative risk ratio (aRRR) for CKD severity categories (≤ 2nd, 2nd–10th, 10th–50th, &gt; 50th eGFR percentile) with RAb were 8.67 (95% <i>CI</i> 2.62–28.64, <i>P</i> = 0.021), 14.26 (95% <i>CI</i> 3.41–59.68, <i>P</i> &lt; 0.001), 5.50 (95% <i>CI</i> 0.55–61.78, <i>P</i> = 0.145), and 26.21 (95% <i>CI</i> 1.64–417.84, <i>P</i> = 0.021). Population attributable fractions of CKD stages 1–5 to <i>Loa</i> microfilaremia was 14.7% (95% <i>CI</i> 4.3–24.0) and 30.1% (95% <i>CI</i> 16.2–42.8) for CKD stages 1–5 with RAb.</p> Conclusions <p>This study provides the first epidemiological evidence linking loiasis to renal impairment, likely via glomerular damage. Given loiasis high endemicity in Central Africa, it may contribute to the burden of unexplained nephropathies. Longitudinal studies and renal biopsies are warranted to clarify underlying mechanisms.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chronic kidney disease related to Loa loa microfilaremia in a rural area of the Republic of Congo: a population-based cross-sectional study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月21日

查看全文
  • Charlotte Boullé,
  • Jérémy T. Campillo,
  • Marlhand C. Hemilembolo,
  • Elodie Lebredonchel,
  • Valentin Dupasquier,
  • Jean Claude Djontu,
  • Sébastien D. S. Pion,
  • Laurène Tardieu,
  • Ludovic Rancé,
  • François Missamou,
  • Francine Ntoumi,
  • Michel Boussinesq,
  • Cédric B. Chesnais

摘要

Background

Loiasis affects millions in Central Africa and, though historically considered benign, emerging data suggest possible renal involvement. This study investigated the association between Loa microfilaremia and renal function.

Methods

We conducted a cross-sectional study in the Republic of Congo in May–June 2022. Renal function was assessed via estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease—Epidemiology Collaboration (CKD-EPI) and European Kidney Function Consortium (EKFC) equations, and proteinuria and/or haematuria (renal abnormalities, RAb). Multinomial logistic regression assessed associations between microfilarial density (MFD) and chronic kidney disease (CKD), using EKFC with Dubois correction. Population attributable fractions were estimated from a logistic model including Loa microfilaremia as a binary variable (present versus absent).

Results

Among 986 participants, CKD prevalence ranged from 13.4% [95% confidence interval (CI) 11.4–15.7%, CKD-EPI] to 17.6% (95% CI 15.3–20.1%, EKFC) for KDIGO stages 1–5, and from 3.0% (95% CI 2.1–4.3%, CKD-EPI) to 7.6% (95% CI 6.1–9.4%, EKFC) for stages 3–5. Loa MFD was associated with higher odds of CKD, particularly in individuals with RAb. Compared to amicrofilaremic participants, those with Loa MFD ≥ 20 000 mf/ml had significantly increased risk: adjusted relative risk ratio (aRRR) for CKD severity categories (≤ 2nd, 2nd–10th, 10th–50th, > 50th eGFR percentile) with RAb were 8.67 (95% CI 2.62–28.64, P = 0.021), 14.26 (95% CI 3.41–59.68, P < 0.001), 5.50 (95% CI 0.55–61.78, P = 0.145), and 26.21 (95% CI 1.64–417.84, P = 0.021). Population attributable fractions of CKD stages 1–5 to Loa microfilaremia was 14.7% (95% CI 4.3–24.0) and 30.1% (95% CI 16.2–42.8) for CKD stages 1–5 with RAb.

Conclusions

This study provides the first epidemiological evidence linking loiasis to renal impairment, likely via glomerular damage. Given loiasis high endemicity in Central Africa, it may contribute to the burden of unexplained nephropathies. Longitudinal studies and renal biopsies are warranted to clarify underlying mechanisms.

Graphical Abstract